News Column

United States : IMMUNE DESIGN files for IPO

June 26, 2014

A Seattle biotechnology company, Immune Design, working on immune-based therapies to fight cancer, filed documents with the Securities and Exchange Commission to go public.

The biotech, on Eastlake Avenue East, said it wants to raise $60 million to finish the phase 1 clinical trials and to support continued development, including into phase 2 clinical trials.

The company's primary research and focus is on targeting tumors and killing them off through the body's immune system. The treatment is done through a series of injections on patients with melanoma, non-small cell lung cancer, breast cancer, ovarian cancer, sarcoma or Merkel cell carcinoma.

Immune Design has three clinic trials ongoing. The most recent, which began in April 2014, is set to be finished in December 2016. The trials are being held at the Seattle Cancer Care Alliance, the University of Washington, and at eight other cancer-research institutes around the nation.

For more stories on investments and markets, please see HispanicBusiness' Finance Channel

Source: TendersInfo (India)

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters